The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity

This publication has 47 references indexed in Scilit:

• A novel interaction between HER2/neu and cyclin E in breast cancer
  Oncogene, 2010
• CD24 and Siglec-10 Selectively Repress Tissue Damage–Induced Immune Responses
  Science, 2009
• Induction of inflammatory and immune responses by HMGB1–nucleosome complexes: implications for the pathogenesis of SLE
  The Journal of Experimental Medicine, 2008
• Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response
  Proceedings of the National Academy of Sciences, 2008
• DNA Vaccination Controls Her-2+ Tumors that Are Refractory to Targeted Therapies
  Cancer Research, 2008
• Adaptive immune cells temper initial innate responses
  Nature Medicine, 2007
• Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
  Nature Medicine, 2007
• Targeting the function of the HER2 oncogene in human cancer therapeutics
  Oncogene, 2007
• Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
  New England Journal of Medicine, 2005
• Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
  Science, 1987